Nicochems Tablet 0.5 mg (Varenicline Tartrate)

Adult dose

Patients should set a quit date and start taking this medicine 1 week before that date. Alternatively, they may start smoking cessation between day 8 and day 35 after starting this medicine. This medicine should be taken after a meal with plenty of water. The recommended dose of this medicine is as follows: after dose titration over 1 week, administer 1 mg 2 times daily. Days 1 – 3 0.5 mg once daily Days 4 – 7 0.5 mg 2 times daily Day 8 – end of treatment 1 mg 2 times daily For patients who cannot tolerate the adverse reactions of this medicine, the dose may be reduced temporarily or permanently. The treatment period for this medicine is 12 weeks. For patients who successfully quit smoking with the first 12 weeks of treatment, it is recommended that this medicine be administered for an additional 12 weeks to increase the likelihood of long-term smoking cessation. For patients who cannot or do not wish to stop smoking abruptly, gradual smoking cessation while taking this medicine may be considered. Within the first 4 weeks after starting this medicine, patients should reduce their smoking by 50% compared with before starting treatment, and reduce it by a further 50% within the following 4 weeks. Smoking should continue to be reduced so that complete smoking cessation is achieved by week 12. Administer this medicine for an additional 12 weeks for a total treatment period of 24 weeks. Encourage patients to stop smoking sooner if they feel ready. Patients who fail to quit smoking with the first 12 weeks of treatment, or who resume smoking after treatment, should review the reasons for failure and try again. However, there are no data demonstrating the efficacy of an additional 12 weeks of treatment in patients who failed to quit smoking during the first 12 weeks of treatment or resumed smoking after treatment. No dose adjustment is required in patients with mild (estimated creatinine clearance > 50 ml/min and ≤ 80 ml/min) to moderate (estimated creatinine clearance ≥ 30 ml/min and ≤ 50 ml/min) renal impairment. In patients with severe renal impairment (estimated creatinine clearance < 30 ml/min), the recommended starting dose of varenicline is 0.5 mg once daily. If needed, the maximum dose is 0.5 mg 2 times daily. In patients with end-stage renal disease receiving hemodialysis, a maximum dose of 0.5 mg once daily may be administered if well tolerated. No dose adjustment is required in patients with hepatic impairment. In elderly patients, renal function is more likely to be reduced, so care should be taken when selecting the dose; monitoring renal function may be useful.

Child dose

Administration is not recommended in patients under 18 years of age.

This medication is used to assist with smoking cessation. During the use of this medication, neuropsychiatric symptoms such as depression, anxiety, aggressive behavior, hallucinations, and suicidal thoughts may occur, hence caution is needed. If such symptoms appear, stop taking the medication immediately and consult a doctor. This medication should not be administered to patients with hypersensitivity, and should be used with caution in pregnant or breastfeeding women. During use, various side effects may occur, including nausea, headache, insomnia, and unusual dreams, and nausea may occur frequently. Patients with a history of seizures or those at risk for seizures should use this medication with greater caution, and should discontinue use immediately if a seizure occurs. While taking this medication, care should be taken when driving or operating machinery, as these activities may be hazardous. Additionally, while there are no major interactions with some medications, it is best to avoid alcohol consumption, as it may exacerbate side effects. Elderly patients may experience decreased kidney function, and dosage adjustments and monitoring of kidney function may be necessary. In cases of overdose, standard treatment should be provided, and the medication should be kept out of reach of children. Finally, it is essential to inform a doctor if there is a history of psychiatric disorders before taking this medication and to observe for neuropsychiatric symptoms when using this medication along with a smoking cessation attempt.

• Suicidal thoughts
• suicidal behavior
• suicide
• changes in behavior or thoughts
• depression
• mania
• psychosis
• aggressive behavior
• hallucinations
• paranoia

This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. It is best to maintain the storage temperature between 1 degree and 30 degrees Celsius at room temperature. This will help to safely preserve the efficacy of the medication.

Appearance

White or grayish white, biconvex, rectangular film-coated tablet

Package unit

11 tablets (11 tablets/BlisterX1)